Skip to main content

Table 4 Treatment approach for ICI-related pneumonitis and reactivity for chest HRCT findings

From: Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

Case Initial treatment Chest HRCT findings
1 0.5 mg/kg prednisolone (p.o.) Disappeared
2 1 mg/kg prednisolone (p.o.) Disappeared
3 0.5 g methylprednisolone (i.v.) × 3 days followed by 1 mg/kg prednisolone (p.o.) Markedly improved
4 3 mg/kg infliximab (i.v.) Markedly improved
5 1 mg/kg prednisolone (p.o.) Markedly improved
6 0.5 mg/kg prednisolone (p.o.) Markedly improved
7 1 mg/kg prednisolone (p.o.) and 3 mg/kg infliximab (i.v.) Disappeared
8 1 mg/kg prednisolone (p.o.) Markedly improved
9 1 mg/kg prednisolone (p.o.) Markedly improved
10 1 mg/kg prednisolone (p.o.) Disappeared
11 1 mg/kg prednisolone (p.o.) Disappeared
12 none Disappeared
  1. Daily dose is as shown for prednisolone and methylprednisolone. The dose of prednisolone was gradually decreased in all patients who underwent corticosteroid treatment. Infliximab was administered with a single dose of 3 mg/kg
  2. HRCT, high-resolution computed tomography; ICI, immune checkpoint inhibitor; i.v., intravenous; p.o., per os (oral administration)